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Recent studies have been reported that angiogenesis suppression may play a role in developing
bisphosphonate-related osteonecrosis of the jaw (B-ONJ). According to these evidence we evaluated the role of
VEGF as predictive marker of B-ONJ onset. Of the 81 patients, 6 developed B-ONJ following bisphosphonate
treatment. These patients showed a strongest decrease in VEGF circulating levels at day 7 and at day 21 after the
first administration. These data demonstrated for the first time that the anti-angiogenic properties of
bisphosphonates are directly linked to B-ONJ pathogenesis and serum VEGF levels could represent an effective early
predictive marker.
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Bisphosphonate-related osteonecrosis of the jaw (B-ONJ)
is defined as non-healing exposed bone in the mandible or
maxilla persisting for more than 8 weeks in a patient with
no history of radiation therapy on the jaws who has taken
or is currently taking a bisphosphonate. B-ONJ is a well-
known adverse effect reported in about 5% of patients
with cancer receiving high-dose intravenous bisphospho-
nates [1].
B-ONJ pathogenesis is still uncertain and under de-
bate; bisphosphonates indeed act on a wide variety of
cells, possibly increasing susceptibility to infections in
the oral cavity and impairing mucosal healing acting on
monocyte differentiation, angiogenesis or both [1].
Recently, several cases of exposed bone in the mandible,
with a very close clinical presentation to B-ONJ, have been
reported in cancer patients treated with bevacizumab, a re-
combinant human monoclonal antibody that binds to vas-
cular endothelial growth factor (VEGF) and inhibits
angiogenesis [2,3]. According to popular hypothesis, angio-
genesis suppression may indeed play a role in B-ONJ [4],
even though evidences are currently lacking. Notably, vas-
cular impairment is considered to be crucial in the* Correspondence: b.vincenzi@unicampus.it
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reproduction in any medium, provided the orpathogenesis of other bisphosphonate-unrelated osteo-
necrosis (e.g. osteoradionecrosis, avascular necrosis of the
hip and corticosteroid-induced osteonecrosis).
Notably, beside known antiresorptive, immunomodu-
lating and direct antitumor actions, bisphosphonates are
now considered to be also anti-angiogenic drugs: in our
three previous works we showed the reduction of circu-
lating VEGF in cancer patients suffering from bone me-
tastases after treatment with either zoledronic acid
(standard schedule or metronomic administration) or
pamidronate [5-7].Findings
In order to evaluate the role of VEGF reduction as pre-
dictive marker of B-ONJ onset, we collected data from
our three series involving a total of 81 patients. Of 81
patients, 6 (7.4%) developed B-ONJ following intraven-
ous bisphosphonate administration (1 under treatment
with pamidronate, 3 under treatment with zoledronic
acid on standard schedule and 2 under treatment with
zoledronic acid on metronomic administration). These 6
patients were affected by breast cancer (n = 3), prostate
cancer (n = 2) and renal cancer (n = 1). The median
number of bisphosphonates administrations was 9 in B-
ONJ group vs. 11 in non-B-ONJ group (p = 0.196) and
the median time of B-ONJ development was 9 months
(range 6–22).l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 VEGF levels (pg/ml) at baseline, 7 and 21 days in
patients who developed B-ONJ
VEGF levels (pg/ml)
Patients baseline 7 days 21 days
#1 804,66 407,82 350,00
#2 995,36 456,97 433,45
#3 970,44 510,11 473,00
#4 847,00 705,09 799,03
#5 932,00 564,23 468,00
#6 883,60 590,70 603,00
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these 6 patients showed the strongest decrease in VEGF
circulating levels at day 7 (median = 540.81, CI95%
129.35-634.64 vs. median = 788.55, CI95% 728.96-870.44,
P < 0.0001) and at day 21 (median = 458.00, CI95%
369.05-601.29 vs. median = 710.81, CI95% 638.66-955.53,
P < 0.0001) after the first administration of either zole-
dronic acid or pamidronate. VEGF levels of the 6
patients are summarized in Table 1. VEGF was assayed
using the R&D quantitative kit according to the manu-
facturer's instructions (R&D Systems, Minneapolis,
MN). The detection limit of the VEGF was 62.5 pg/ml.
To the best of our knowledge, this is the first evi-
dence that the anti-angiogenic properties of bispho-
sphonates are directly linked to B-ONJ pathogenesis.
If confirmed, serum VEGF levels at day 7 and 21
after the first administration of intravenous bispho-
sphonate could represent an effective early predictive
marker of B-ONJ.Finally, we are aware that these
data come from a very small retrospective analysis,
but their potential impact in clinical practice war-
rants prospective studies and extensive validation by
the entire medical community.
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